High-Activity Factor IX Subcutaneous Formulation Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Subcutaneous administration of Factor IX for treating bleeding disorders like hemophilia B faces challenges due to limitations in volume per administration site and significant bioavailability loss compared to intravenous routes, with high concentrations risking local tolerability issues such as thrombus formation.
Innovation Solution
Administering high-activity Factor IX variants at lower protein concentrations, potentially linked with half-life enhancers like albumin, to achieve high activity levels with reduced protein load per injection site, minimizing local tolerability issues and improving safety and comfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high FIX activity doses are administered subcutaneously to achieve effective prophylaxis or treatment, then the therapeutic efficacy is improved, but the risk of local tolerability issues such as thrombus formation increases
Solution Approach 1:
The patent applies parameter changes by modifying the FIX protein concentration parameter. Instead of administering high FIX activity through high protein concentration, the invention uses high-activity FIX variants (such as the Padua mutant with R338L substitution) that provide the necessary therapeutic efficacy at lower protein concentrations (≤20 mg/mL), thereby resolving the contradiction between therapeutic efficacy and local tolerability
Solution Approach 2:
The patent introduces half-life enhancers as intermediary substances that mediate between the FIX variant and the patient's system. These enhancers (such as albumin fusion proteins, PEGylation, or Fc fusion) extend the circulation half-life of FIX, allowing lower doses to achieve sustained therapeutic levels, thus reducing the need for high local concentrations at injection sites
2Volume of moving object
If FIX is administered at high protein concentration to deliver sufficient activity, then the volume per injection is reduced, but the risk of excessive local clotting increases
Solution Approach 1:
The patent changes the specific activity parameter of FIX by using high-activity variants. The Padua mutant (R338L) and other high-activity variants provide 2-5 times higher specific activity than wild-type FIX, enabling the delivery of sufficient therapeutic activity at lower protein concentrations and smaller volumes, thereby avoiding excessive local clotting
Solution Approach 2:
The patent employs disposable high-activity FIX variants that can be administered in small volumes. These variants are designed to be highly potent but are used in controlled, limited quantities at each injection site, providing effective therapy without the need for large-volume, high-concentration administrations that would cause local complications
3Quantity of substance
If multiple subcutaneous administration sites are used to deliver high FIX activity, then the total dose is achieved, but patient comfort and compliance deteriorate
Solution Approach 1:
The patent modifies the concentration parameter to enable highly concentrated formulations (≤20 mg/mL protein concentration) that can deliver the required total FIX activity dose in smaller volumes. This allows the entire dose to be administered at fewer sites or even at a single site, significantly improving patient comfort and compliance while maintaining the necessary total dose
Data Source
AI summary
This invention relates to Factor IX compositions and their uses in therapy by subcutaneous administration. In particular, high-activity Factor IX compositions for subcutaneous administration comprising advantageous Factor IX protein concentrations are provided, which minimize the risk of local tolerability issues, thereby providing enhanced safety.